ONCOLOGY

The association did not apply to hyperparathyroidism-related hypercalcemia.

Data from 10,805 NHL cases and 14,026 controls contradict earlier meta-analysis.

Study finds 2 significant factors for appropriate patients.

Unprecedented high and durable MRD negativity in elderly patients with comorbidities.

Durable MRD negativity in peripheral blood.

6-year follow-up of the phase 3 RESONATE trial.

High rate of disenrollment because of adverse events.

High-quality response and MRD negativity also seen with KRd12.

Post hoc analysis of frailty subgroups from phase 3 ASPIRE and ENDEAVOR.

98% reduction in peripheral blasts at day 3.

Combination was approved by FDA on May 28, 2019.

ADMIRAL study shows survival benefit across major ITD3 comutations.

Many patients generally maintained or deepened response.

Data from the UK RAPID study